Drugmaker Merck & Co. said that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.
Bristol-Myers Squibb Co. said it will acquire biotechnology partner ZymoGenetics Inc. for $885 million in another move by a major drugmaker to boost its pipeline by snapping up a smaller developer.
Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.
CEM Corporation, a leading global provider of microwave laboratory instrumentation, has announced the introduction of its UV Monitoring System, which is designed to work with CEM’s Liberty and Liberty1 Microwave Peptide Synthesizers.
Bio-Rad Laboratories announced the launch of the Gel Doc EZ, a compact gel documentation system that provides publication-quality images and analysis in seconds — with just the push of a button.
West, a premier manufacturer of components and systems for injectable drug delivery, and Grifols USA, LLC announced the availability of West’s Mix2Vial filtered transfer system for the reconstitution of Grifols’ coagulation therapies.
Emerald BioStructures and SomaLogic, Inc. announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.
Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells. Many of the side effects experienced by chemotherapy patients are due to the fact that the drugs they are taking aren't selective enough.
A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood.
Promedior, Inc. has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.
Orexigen Therapeutics Inc. has signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals. Under the deal, Orexigen will receive $50 million upfront from Takeda, Japan's largest drugmaker.
Drug and medical device firm Abbott Laboratories said it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.
It's hard to predict which pills will best lower which patient's high blood pressure, but researchers are hunting ways to better personalize therapy - perhaps even using a blood test. The work is controversial, challenging today's usual approach to treating the hypertension that plagues nearly one in three U.S. adults.
People who take bone-strengthening drugs for several years may have a slightly higher risk of esophageal cancer, a new study suggests. The findings are in contrast to another recent study that used the same database of 80,000 patients and found no link between the drugs and esophageal cancer.
The vaccine used to contain the recent swine flu pandemic was effective, but health authorities will need to ramp up the speed and volume of production during the next global outbreak, a World Health Organization official said.